The article reports on the partnership of Parexel International Corp. and Merck BioVentures. It mentions that the deal would allow Parexel in providing regulatory clinical development planning to Merck BioVentures which aims to have five potential products in last-stage clinical trials by 2012. It also notes that the agreement of both companies has proved that manufacturers does not wait for a formal guidance when opportunity comes knocking.